--- title: Takara Bio Europe Introduces GMP-Grade Cellartis® MSC EV Wonder™ to Support Clinical-Scale Extracellular Vesicle Production description: Takara Bio Europe launches GMP-grade Cellartis MSC EV Wonder, a defined, xeno-free medium for scalable extracellular vesicle production from human MSCs. image: https://news.lifesciencenewswire.com/hubfs/Takara%20Bio%20Europe_logo.png --- [![Life Science Newswire 2](https://news.lifesciencenewswire.com/hs-fs/hubfs/Life%20Science%20Newswire%202.png?width=203&height=60&name=Life%20Science%20Newswire%202.png "Life Science Newswire 2")](https://lifesciencenewswire.com/) - [Newsroom](https://news.lifesciencenewswire.com/newsroom) - [Back to the main site](https://lifesciencenewswire.com/) ![LSNewswire-main-header-banner-v2-1](https://news.lifesciencenewswire.com/hubfs/LSNewswire-main-header-banner-v2-1.jpg "LSNewswire-main-header-banner-v2-1") # Newsroom #### Categories ![Arrow](https://cdn2.hubspot.net/hubfs/3842749/ps4-Pack/sidebar.svg "Arrow") #### Subscribe![](https://cdn2.hubspot.net/hubfs/3842749/ps4-Pack/subscribe-rss-button.svg) ![](https://cdn2.hubspot.net/hubfs/3842749/ps4-Pack/close-button.svg) ### Choose a Category - [Agriculture (1)](https://news.lifesciencenewswire.com/newsroom/tag/agriculture) - [AI (2)](https://news.lifesciencenewswire.com/newsroom/tag/ai) - [Analytical Chemistry (42)](https://news.lifesciencenewswire.com/newsroom/tag/analytical-chemistry) - [Biomanufacturing (36)](https://news.lifesciencenewswire.com/newsroom/tag/biomanufacturing) - [biopharma (23)](https://news.lifesciencenewswire.com/newsroom/tag/biopharma) - [Bioprocessing (16)](https://news.lifesciencenewswire.com/newsroom/tag/bioprocessing) - [Biotechnology (253)](https://news.lifesciencenewswire.com/newsroom/tag/biotechnology) - [Cell Culture (10)](https://news.lifesciencenewswire.com/newsroom/tag/cell-culture) - [Clinical Diagnostics (38)](https://news.lifesciencenewswire.com/newsroom/tag/clinical-diagnostics) - [clinical research (6)](https://news.lifesciencenewswire.com/newsroom/tag/clinical-research) - [Clinical Research & Trials (118)](https://news.lifesciencenewswire.com/newsroom/tag/clinical-research-trials) - [Computing & Technology (62)](https://news.lifesciencenewswire.com/newsroom/tag/computing-it) - [Corporate, Finance & Investor (289)](https://news.lifesciencenewswire.com/newsroom/tag/corporate-finance-investor) - [COVID-19 (86)](https://news.lifesciencenewswire.com/newsroom/tag/covid-19) - [Diagnostics & Hospital Laboratory (38)](https://news.lifesciencenewswire.com/newsroom/tag/diagnostics-hospital-laboratory) - [Digital Pathology (2)](https://news.lifesciencenewswire.com/newsroom/tag/digital-pathology) - [Drug Discovery & Development (154)](https://news.lifesciencenewswire.com/newsroom/tag/drug-discovery-development) - [Energy & Environment (15)](https://news.lifesciencenewswire.com/newsroom/tag/energy-environment) - [excipients (1)](https://news.lifesciencenewswire.com/newsroom/tag/excipients) - [Food & Beverage (8)](https://news.lifesciencenewswire.com/newsroom/tag/food-beverage) - [General Chemistry (7)](https://news.lifesciencenewswire.com/newsroom/tag/general-chemistry) - [General Laboratory (58)](https://news.lifesciencenewswire.com/newsroom/tag/general-laboratory) - [General Science (5)](https://news.lifesciencenewswire.com/newsroom/tag/general-science) - [Healthcare (137)](https://news.lifesciencenewswire.com/newsroom/tag/healthcare) - [Hospital Management (7)](https://news.lifesciencenewswire.com/newsroom/tag/hospital-management) - [Life Science (26)](https://news.lifesciencenewswire.com/newsroom/tag/life-science) - [Manufacturing (2)](https://news.lifesciencenewswire.com/newsroom/tag/manufacturing) - [Materials Science (2)](https://news.lifesciencenewswire.com/newsroom/tag/materials-science) - [Medical Devices & Technology (27)](https://news.lifesciencenewswire.com/newsroom/tag/medical-devices-technology) - [Microbiology & Infection Control (18)](https://news.lifesciencenewswire.com/newsroom/tag/microbiology-infection-control) - [Microscopy & Imaging (47)](https://news.lifesciencenewswire.com/newsroom/tag/microscopy-imaging) - [Nanotech (2)](https://news.lifesciencenewswire.com/newsroom/tag/nanotech) - [Omics & Genetics (88)](https://news.lifesciencenewswire.com/newsroom/tag/omics-genetics) - [Pathology (5)](https://news.lifesciencenewswire.com/newsroom/tag/pathology) - [Pharma (118)](https://news.lifesciencenewswire.com/newsroom/tag/pharma) - [Pharmacy (5)](https://news.lifesciencenewswire.com/newsroom/tag/pharmacy) - [Research (47)](https://news.lifesciencenewswire.com/newsroom/tag/research) - [Veterinary (6)](https://news.lifesciencenewswire.com/newsroom/tag/veterinary) - [Water (8)](https://news.lifesciencenewswire.com/newsroom/tag/water) See all ### Subscribe to Email Updates - ##### SHARE - - - # [Takara Bio Europe Introduces GMP-Grade Cellartis® MSC EV Wonder™ to Support Clinical-Scale Extracellular Vesicle Production](https://news.lifesciencenewswire.com/newsroom/takara-bio-europe-introduces-gmp-grade-cellartis-msc-ev-wonder-to-support-clinical-scale-extracellular-vesicle-production) October 28, 2026 Takara Bio Europe announces the introduction of a Good Manufacturing Practice (GMP)-grade version of Cellartis® MSC EV Wonder™, its defined, xeno-free medium developed for the efficient and scalable production of extracellular vesicles (EVs) from human mesenchymal stem cells (MSCs). The addition of a GMP-grade version expands the Cellartis portfolio, supporting the transition from early-stage EV research towards clinical development and manufacturing applications. MSC-derived EVs are gaining increasing attention as promising candidates for next-generation cell-free therapies, particularly in regenerative medicine, immunomodulation and drug delivery. However, translating EV-based approaches from laboratory research to clinical applications requires consistent production processes, reproducible product quality and suitable manufacturing materials. Originally developed to address challenges in EV yield and reproducibility, Cellartis MSC EV Wonder has demonstrated up to a nine-fold increase in EV production compared with conventional DMEM while maintaining essential EV characteristics, including canonical CD marker expression, morphology and RNA profiles. Its defined, phenol red-free formulation shares the same basal medium as the Cellartis MSC Xeno-Free Culture System, facilitating a streamlined workflow from MSC expansion to EV production. With the introduction of the GMP-grade version, Takara Bio Europe aims to further support developers seeking to establish robust and scalable MSC-EV manufacturing workflows. The availability of GMP-grade medium provides an additional option for organizations advancing EV-based applications towards clinical translation, where material quality, process consistency and manufacturing controls become increasingly important. "As interest in extracellular vesicle-based therapeutics continues to grow, the need for reliable and scalable manufacturing solutions becomes increasingly important," said Tarik Hadi, PhD, Senior Market Strategy Manager at Takara Bio Europe. "By expanding Cellartis MSC EV Wonder with a GMP-grade option, we are strengthening our support for developers working to bridge the gap between scientific discovery and clinical translation." The GMP-grade version of Cellartis MSC EV Wonder™ is scheduled for launch on 28 October 2026. Researchers and organizations interested in learning more about the medium, its applications or technical specifications are encouraged to contact Takara Bio Europe at [infoEU@takarabio.com](mailto:infoEU@takarabio.com). **About Takara Bio** Takara Bio Europe, a subsidiary of Takara Bio Inc., is a leading manufacturer and supplier of molecular and cellular biology reagents and services. Its portfolio supports applications including NGS, cloning, viral transduction, protein expression and purification, gene editing, nucleic acid extraction and stem cell research. Key products include SMART NGS kits for DNA- and RNA-seq, Cellartis cell culture reagents, high-performance qPCR and PCR reagents, RT enzymes, and the innovative In-Fusion® cloning system. Takara Bio has recently expanded its capabilities to include spatial transcriptomics, complementing its existing expertise in NGS R&D, manufacturing and automation solutions for NGS and qPCR applications. For more information, visit [www.takarabio.com](http://www.takarabio.com/). **About Takara Bio Inc.** Takara Bio Inc., a world leader in biotechnology research and development, offers a host of life science research solutions, from enzymes and GMP-grade reagents to contracted cell and gene therapy manufacturing services, and is the developer of the RetroNectin® reagent, a world standard in gene therapy protocols. Takara Bio is committed to preventing disease and improving the quality of life for all people through the use of biotechnology. Categories: [Bioprocessing](https://news.lifesciencenewswire.com/newsroom/tag/bioprocessing), [Biomanufacturing](https://news.lifesciencenewswire.com/newsroom/tag/biomanufacturing), [Biotechnology](https://news.lifesciencenewswire.com/newsroom/tag/biotechnology) ##### Browse more news ## Recent releases #### [Takara Bio Europe Introduces GMP-Grade Cellartis® MSC EV Wonder™ to Support Clinical-Scale Extracell...](https://news.lifesciencenewswire.com/newsroom/takara-bio-europe-introduces-gmp-grade-cellartis-msc-ev-wonder-to-support-clinical-scale-extracellular-vesicle-production) October 28, 2026 Takara Bio Europe announces the introduction of a Good Manufacturing Practice (GMP)-grade version of Cellartis® MSC EV Wonder™, its defined, xeno-free... ##### [READ MORE](https://news.lifesciencenewswire.com/newsroom/takara-bio-europe-introduces-gmp-grade-cellartis-msc-ev-wonder-to-support-clinical-scale-extracellular-vesicle-production) #### [Samplix Secures Backing to Accelerate Xdrop’s Commercial Expansion in Antibody Discovery](https://news.lifesciencenewswire.com/newsroom/samplix-secures-backing-to-accelerate-xdrops-commercial-expansion-in-antibody-discovery) October 27, 2026 WLan-led financing reaches a €25 million first closing, comprising €3 million in new capital and €22 million in shareholder convertible-bond conversio... ##### [READ MORE](https://news.lifesciencenewswire.com/newsroom/samplix-secures-backing-to-accelerate-xdrops-commercial-expansion-in-antibody-discovery) #### [Ceryx Medical manufactures first implantable heart failure device at King’s College London’s MAISI f...](https://news.lifesciencenewswire.com/newsroom/ceryx-medical-manufactures-first-implantable-heart-failure-device-at-kings-college-londons-maisi-facility) October 22, 2026 A first for both organisations: the first implantable device built by the UK’s national active implant manufacturing facility is Ceryx’s bioelectronic... ##### [READ MORE](https://news.lifesciencenewswire.com/newsroom/ceryx-medical-manufactures-first-implantable-heart-failure-device-at-kings-college-londons-maisi-facility) ![LS-Newswire-reverse](https://news.lifesciencenewswire.com/hs-fs/hubfs/raw_assets/public/LifeScienceNewswire_June2020/images/LS-Newswire-reverse.png?width=150&name=LS-Newswire-reverse.png "LS-Newswire-reverse") Life Science Newswire is a division of BioStrata Ltd, with company registered address: 3rd Floor, 1 Ashley Road, Altrincham, Cheshire, England, WA14 2DT. Company registration number: 8233225  #### Useful information - [Cookie and privacy policy](https://lifesciencenewswire.com/cookie-privacy-policy/) - [Website terms and conditions](https://lifesciencenewswire.com/terms-and-conditions) - [Promotion terms and conditions](https://lifesciencenewswire.com/promotion_terms/)